

# CK-MB STAT

CK-MB - the MB isoenzyme of creatine kinase (STAT "Short Turn Around Time")

REF	$\Sigma$	SYSTEM
11731432 122	100	Elecsys 2010 <b>cobas e 411</b> <b>cobas e 601</b> <b>cobas e 602</b>

## English

### Intended use

Immunoassay for the in vitro quantitative determination of the MB isoenzyme of creatine kinase in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

### Summary

Creatine kinase (CK) is a dimeric enzyme which occurs in four different forms: a mitochondrial isoenzyme and the cytosolic isoenzymes CK-MM (muscle type), CK-BB (brain type) and CK-MB.<sup>1,2</sup>

The determination of CK-MB mass in serum is an important element in the diagnosis of myocardial ischemia, e.g. in acute myocardial infarction, myocarditis, etc.<sup>1,2</sup> CK-MB is detectable in the blood about 3-8 hours after the onset of cardiac symptoms and can remain detectable over a lengthy period of time, depending on the course of the condition.<sup>1</sup>

CK-MB may also appear in other clinical conditions, e.g. in rhabdomyolysis and stroke.<sup>1</sup> Within the scope of laboratory diagnostics, the determination of total CK, troponin T and/or myoglobin can contribute to the differentiation of these clinical pictures.

The sensitivity of a CK-MB determination is dependent upon the time at which a sample was taken. Follow-up assays are therefore meaningful.<sup>1,3</sup>

The Elecsys CK-MB STAT assay employs two different monoclonal antibodies directed against human CK-MB.

### Test principle

Sandwich principle. Total duration of assay: 9 minutes.

Elecsys 2010 and **cobas e 411** analyzers:

- 1st incubation: 15 µL of sample, a biotinylated monoclonal anti-CK-MB antibody, and a monoclonal CK-MB-specific antibody labeled with a ruthenium complex<sup>a)</sup> react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

**cobas e 601** and **cobas e 602** analyzers:

- During a 9 minute incubation, antigen in the sample (15 µL), a biotinylated monoclonal anti-CK-MB antibody, a monoclonal CK-MB-specific antibody labeled with a ruthenium complex and streptavidin-coated microparticles react to form a sandwich complex, which is bound to the solid phase.

All analyzers:

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

### Reagents - working solutions

The reagent rackpack is labeled as CKMBSTAT.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-CK-MB-Ab-biotin (gray cap), 1 bottle, 10 mL: Biotinylated monoclonal anti-CK-MB antibody (mouse) 1.2 mg/L; phosphate buffer 100 mmol/L, pH 7.0; preservative.
- R2 Anti-CK-MB-Ab-Ru(bpy)<sub>3</sub><sup>2+</sup> (black cap), 1 bottle, 10 mL: Monoclonal anti-CK-MB antibody (mouse) labeled with ruthenium complex 1.2 mg/L; phosphate buffer 100 mmol/L, pH 7.0; preservative.

### Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

### Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

### Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	8 weeks

### Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, Na-heparin, K<sub>3</sub>-EDTA and sodium citrate plasma. When sodium citrate is used, the results must be corrected by + 10 %.

Criterion: Recovery within 90-110 % of serum value or slope 0.9-1.1 + intercept within < ± 2x analytical sensitivity (LDL) + coefficient of correlation > 0.95.

Stable for 4 hours at 18-23 °C, 8 hours at 2-8 °C, 3 months at -20 °C.

Freeze only once.

CK-MB stability is extremely temperature-dependent. A CK-MB decrease of > 10 % can occur after the sample has stood for 1 hour at 32 °C.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.



# CK-MB STAT

## CK-MB - the MB isoenzyme of creatine kinase (STAT "Short Turn Around Time")

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

### Materials provided

See "Reagents – working solutions" section for reagents.

### Materials required (but not provided)

- [REF] 11731572122, CK-MB STAT CalSet, for 4 x 1 mL
- [REF] 04917049190, PreciControl Cardiac II, for 2 x 2 mL each of PreciControl Cardiac II 1 and 2
- [REF] 04917049160, PreciControl Cardiac II, for 2 x 2 mL each of PreciControl Cardiac II 1 and 2 (for USA)
- [REF] 11732277122, Diluent Universal, 2 x 16 mL sample diluent or [REF] 03183971122, Diluent Universal, 2 x 36 mL sample diluent
- [REF] 03609987190, Diluent MultiAssay, 2 x 16 mL sample diluent
- General laboratory equipment
- Elecsys 2010 or **cobas e** analyzer

Accessories for Elecsys 2010 and **cobas e** 411 analyzers:

- [REF] 11662988122, ProCell, 6 x 380 mL system buffer
- [REF] 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution
- [REF] 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive
- [REF] 11933159001, Adapter for SysClean
- [REF] 11706802001, Elecsys 2010 AssayCup, 60 x 60 reaction vessels
- [REF] 11706799001, Elecsys 2010 AssayTip, 30 x 120 pipette tips

Accessories for **cobas e** 601 and **cobas e** 602 analyzers:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF] 12102137001, AssayTip/AssayCup Combimagazine M, 48 magazines x 84 reaction vessels or pipette tips, waste bags
- [REF] 03023150001, WasteLiner, waste bags
- [REF] 03027651001, SysClean Adapter M

Accessories for all analyzers:

- [REF] 11298500316, Elecsys SysClean, 5 x 100 mL system cleaning solution
- [REF] 11298500160, Elecsys SysClean, 5 x 100 mL system cleaning solution (for USA)

### Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles prior to use and the reading in of the test-specific parameters via the reagent barcode take place automatically. No manual input is necessary. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

Bring the cooled reagents to approx. 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

### Calibration

**Traceability:** The linearity of the Elecsys CK-MB STAT assay was improved by using human recombinant CK-MB<sup>4</sup> from Seradyn ([REF] AKC0325; Lot No. M25082). The test was standardized against the previous Elecsys CK-MB STAT assay in the range of 0-20.0 ng/mL; this leads up to a 30 % reduction of the test results in the range of 20.0-500 ng/mL (see graph under Method comparison).

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

**Calibration frequency:** Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

### Quality control

For quality control, use PreciControl Cardiac II.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

### Calculation

The analyzer automatically calculates the analyte concentration of each sample in ng/mL.

### Limitations - interference

The assay is unaffected by icterus (bilirubin < 581 µmol/L or < 34 mg/dL), hemolysis (Hb < 0.932 mmol/L or < 1.5 g/dL), lipemia (Intralipid < 1500 mg/dL) and biotin (< 409 nmol/L or < 100 ng/mL).

**Criterion:** Recovery within ± 10 % of initial value.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 1500 IU/mL and samples from dialysis patients.

There is no high-dose hook effect at CK-MB concentrations up to 5000 ng/mL.

In vitro tests were performed on 50 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.



# CK-MB STAT

CK-MB - the MB isoenzyme of creatine kinase (STAT "Short Turn Around Time")

**cobas**<sup>®</sup>

## Limits and ranges

### Measuring range

0.100-500 ng/mL (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 0.100 ng/mL. Values above the measuring range are reported as > 500 ng/mL (or up to 1000 ng/mL for 2-fold diluted samples).

### Lower limits of measurement

#### Lower detection limit of the test

Lower detection limit: < 0.100 ng/mL

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations above that of the lowest standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 21).

### Dilution

Samples with CK-MB concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:2 (either automatically by the Elecsys 2010 or **cobas e** analyzers, or manually).

On the **cobas e** 601 and **cobas e** 602 analyzers, Diluent MultiAssay can also be used. The concentration of the diluted sample must be > 50.0 ng/mL.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the Elecsys 2010 and **cobas e** software automatically takes the dilution into account when calculating the sample concentration.

### Expected values

In studies with the Elecsys CK-MB STAT assay the following results were obtained (ng/mL):

	N	Median	97.5 <sup>th</sup> percentile	99 <sup>th</sup> percentile
Women	760	0.97	2.88	3.77
Men	628	1.35	4.94	6.73

Data (status July 1999) combined from: FRISC II (Fragmin during instability in coronary artery disease) study, results from Uppsala, January 1999, and International Elecsys 1010 study, cardiac marker, March 1999.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

### Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

### Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a modified protocol (EP5-A) of the CLSI (Clinical and Laboratory Standards Institute): 6 times daily for 10 days (n = 60). The following results were obtained:

Elecsys 2010 and <b>cobas e</b> 411 analyzers					
Sample	Mean	Repeatability		Intermediate precision	
		SD	CV	SD	CV
	ng/mL	ng/mL	%	ng/mL	%
Human serum 1	5.77	0.09	1.5	0.13	2.3
Human serum 2	12.4	0.26	2.1	0.32	2.6
Human serum 3	39.7	0.73	1.8	0.91	2.3
PreciControl Card1	5.86	0.11	1.9	0.14	2.4
PreciControl Card2	53.1	0.99	1.9	1.26	2.7

Precision was determined using Elecsys reagents, samples and controls in a protocol (EP5-A2) of the CLSI (Clinical and Laboratory Standards

Institute): 2 runs per day in duplication each for 21 days (n = 84). The following results were obtained:

<b>cobas e</b> 601 and <b>cobas e</b> 602 analyzers					
Sample	Mean	Repeatability		Intermediate precision	
		SD	CV	SD	CV
	ng/mL	ng/mL	%	ng/mL	%
Human serum 1	1.38	0.04	2.8	0.08	5.5
Human serum 2	2.16	0.04	2.0	0.08	3.7
Human serum 3	3.65	0.07	1.8	0.12	3.2
Human serum 4	8.64	0.25	2.9	0.31	3.6
Human serum 5	361	8.69	2.4	12.2	3.4
PreciControl Card1	4.02	0.06	1.6	0.09	2.3
PreciControl Card2	54.8	0.96	1.8	0.99	1.8

### Method comparison

A comparison of the Elecsys CK-MB STAT assay - linearized (y) with the Elecsys CK-MB STAT assay - previous version (x) using clinical samples gave the following correlations:

- Sample concentrations between 0 and 20.0 ng/mL


Number of samples measured: 366

Passing/Bablok <sup>5</sup>	Linear regression
y = 0.96x + 0.24	y = 0.93x + 0.32
r = 0.958	r = 0.999

- Sample concentrations between 0 and 500 ng/mL

Number of samples measured: 479

### Elecsys CK-MB STAT assay



x: Elecsys CK-MB STAT assay - previous test version - ng/mL

y: Elecsys CK-MB STAT assay - linearized - ng/mL

The new values in the upper concentration range must be taken into consideration when monitoring and estimating the magnitude of an infarction with Elecsys CK-MB STAT assays.

### Analytical specificity

For the monoclonal antibodies used, the following cross-reactivities were found:

CK-MM none, CK-BB 0.10 %.

### References

- Rozenman Y, Gotsman MS. The earliest diagnosis of acute myocardial infarction. Annu Rev Med 1994;45:31-44.



# CK-MB STAT

## CK-MB - the MB isoenzyme of creatine kinase (STAT "Short Turn Around Time")






- 2 Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: Is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-763.
- 3 Apple FS. Diagnostic markers for detection of acute myocardial infarction and reperfusion. Laboratory Medicine 1992;23(5):297-322.
- 4 Christenson RH, Vaidya H, Landt Y, et al. Standardization of Creatine Kinase-MB (CK-MB) Mass Assays: The Use of Recombinant CK-MB as a Reference Material. Clin Chem 1999;45(9):1414-1423.
- 5 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

### Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing

### FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2013, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
www.roche.com

Distribution in USA by:  
Roche Diagnostics, Indianapolis, IN  
US Customer Technical Support 1-800-428-2336

